Small Cell Lung Cancer After a Remote Chest Gunshot Injury

Patient Info: Anonymized, male

Three years after surgery, surveillance imaging showed no signs of recurrence and he described himself as doing well.

PubMed CentralRead more →

Stage IA2 lung adenocarcinoma followed by benign necrotizing sarcoid granulomatosis mimicking recurrence

Patient Info: Anonymized, Male, 60s

Postoperative enlarging nodules suspicious for recurrence were resected and diagnosed as necrotizing sarcoid granulomatosis, so observation continued without glucocorticoid therapy.

PubMed CentralRead more →

Stage IA1 lung adenocarcinoma: disease-free after VATS right lower lobectomy

Patient Info: Anonymized, Male, 70+

Biomarkers: No molecular biomarkers reported; final pathology pT1aN0M0 with no lymph node metastases

Final pathology showed pT1aN0M0 Stage IA1 lung adenocarcinoma with no lymph node metastases, and he remained disease-free at 1-year follow-up.

PubMed CentralRead more →

EGFR Non-Small Cell Lung Cancer: Michelle's Patient Story

Patient Info: Michelle Vacca, Female, 40s

Biomarkers: EGFR mutation at recurrence; later rare mutation not named

As of November 2025, Michelle still actively had recurrent NSCLC, but her disease had remained stable on targeted therapy and an investigational kinase inhibitor clinical trial, allowing good quality of life.

City of HopeRead more →

Second primary Stage I lung adenocarcinoma treated with segmentectomy and adjuvant pembrolizumab

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: PD-L1 <1%; no common targetable lung cancer changes found in EGFR, ALK, KRAS, BRAF, MET, PIK3CA, RET, ROS1, or NTRK.

At 6-month oncologic follow-up, PET-CT showed complete metabolic response with no evidence of residual disease after segmentectomy and adjuvant pembrolizumab.

PubMed CentralRead more →

Stage IIIB RET-fusion lung adenocarcinoma: disease-free after pralsetinib, surgery and maintenance therapy

Patient Info: Anonymized, Male, Under 40 | Stage III

Biomarkers: RET exon 12 fusion. Lung-origin markers were present

After neoadjuvant pralsetinib, surgery showed pathological complete response with negative lymph nodes. As of 16 April 2025, surveillance imaging showed no recurrence while he remained on pralsetinib 300 mg once daily.

PubMed CentralRead more →

Lung Carcinoid Surgery in a Woman With an Absent Left Pulmonary Artery

Patient Info: Anonymized, female, 70+

At 3 months after surgery, her cardiopulmonary function remained stable and no residual postoperative complications were identified.

PubMed CentralRead more →

Two Lung Cancer Patients Who Developed Bullous Pemphigoid During Pembrolizumab — Case 1

Patient Info: Anonymized, male, 70+

Biomarkers: PD-L1 TPS 5%

At the last follow-up, he was alive and continuing chemotherapy after later cancer progression, with no recurrence of bullous pemphigoid.

PubMed CentralRead more →

Stage IVB EGFR-mutated lung adenocarcinoma with brain metastases: complete response and pathologic complete response

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Lung adenocarcinoma with EGFR L858R, PD-L1 TPS 95%

Metastatic Site: brain

Brain metastases achieved complete response on imaging, and surgery after systemic therapy showed pathologic complete response, ypT0N0M0 with 0/13 lymph nodes involved.

PubMed CentralRead more →

Stage IVA EGFR-mutant lung adenocarcinoma: response to triple targeted therapy and surgery

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial EGFR exon 19 deletion; acquired BRAF V600E mutation in progressive lesion while EGFR exon 19 deletion persisted

Metastatic Site: pleura, pulmonary metastases; mediastinal and left…

As of May 2025, she continued osimertinib, dabrafenib, and trametinib after segmentectomy/lymphadenectomy, with 1% viable residual tumor in resected lung lesions, complete nodal pathologic response, and no disease progression.

PubMed CentralRead more →

ALK-fusion lung adenocarcinoma with pleural progression: alectinib toxicity and switch to lorlatinib

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EML4::ALK fusion positive

Metastatic Site: pleura

After pleural progression, disease was stable on ALK-targeted therapy; lorlatinib was tolerated after alectinib-related hemolysis and bradycardia resolved.

PubMed CentralRead more →

EGFR L858R lung adenocarcinoma presenting as rectal and peritoneal metastases

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: Rectal/peritoneal tumors supported lung origin. Key result: EGFR L858R with TP53 mutations; no other actionable lung alteration reported.

Metastatic Site: rectum; peritoneum; omentum; mesentery; colonic wall

After transverse colostomy and confirmation of EGFR L858R-mutant lung adenocarcinoma metastasis, aumolertinib led to clinical stabilization; palliative radiotherapy was later given to the rectal lesion, but long-term follow-up was not yet available.

PubMed CentralRead more →

KRAS G12C lung adenocarcinoma with hypertrophic pulmonary osteoarthropathy: no recurrence after lobectomy

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: KRAS detected; PD-L1 <1%

At 1-year follow-up, there was no evidence of recurrence; pain, edema, grip strength, and periosteal thickening related to hypertrophic pulmonary osteoarthropathy improved after surgery.

PubMed CentralRead more →

Stage IIIA KRAS p.G12V lung adenocarcinoma: pathologic complete response after chemoimmunotherapy and surgery

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: KRAS p.G12V mutation; PD-L1 0% tumor-cell staining; <1% tumor-associated inflammatory-cell staining; no EGFR, ALK, or ROS1 driver mutation reported

Pathology after lobectomy showed a pathologic complete response, and surveillance imaging 12 months later showed no evidence of disease recurrence.

PubMed CentralRead more →

Stage IIIA lung adenocarcinoma complicated by severe atezolizumab-induced liver toxicity

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: PD-L1 49%; case text describes triple-negative status without expanding the specific markers

The patient was discharged clinically stable but with guarded prognosis after atezolizumab-induced vanishing bile duct syndrome, requiring prednisone, mycophenolate mofetil, ursodeoxycholic acid, prophylaxis, and close oncology/internal medicine follow-up.

PubMed CentralRead more →

Lung adenocarcinoma surgery complicated by postoperative chest wall hernia

Patient Info: Anonymized, Male, 70+

He completed VATS left lower lobectomy for lung adenocarcinoma and later mesh repair of a postoperative chest wall hernia; at 6 months after hernia repair, the hernia had not recurred.

PubMed CentralRead more →

Localized lung adenocarcinoma: lobectomy followed by air-leak repair

Patient Info: Anonymized, Male, 60s

After lobectomy and a second thoracoscopic repair for persistent postoperative air leak, the air leak resolved by postoperative day 3 and had not recurred at 2-month follow-up.

PubMed CentralRead more →

Metastatic lung adenocarcinoma with brain and iliac bone response to chemoimmunotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1-negative; no EGFR, ALK, ROS1, RET, KRAS, BRAF, MET, HER2, or NTRK alteration detected; TP53 mutation found.

Metastatic Site: left iliac bone, brain

Brain metastases achieved complete remission without cranial irradiation, and lung, bone, and brain lesions remained stable at last follow-up, with PFS of 35 months and OS exceeding 40 months.

PubMed CentralRead more →

Recurrent lung adenocarcinoma with bevacizumab-associated glomerular microangiopathy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: No tumor molecular biomarkers reported. Kidney biopsy and complement/immune deposits supported bevacizumab-related kidney microangiopathy.

Metastatic Site: pleura

He was living with recurrent metastatic lung adenocarcinoma after pleural spread and had persistent renal dysfunction and severe proteinuria from bevacizumab-associated glomerular microangiopathy despite stopping bevacizumab.

PubMed CentralRead more →

Stage 1 lung adenocarcinoma: no evidence of disease after surgery

Patient Info: Anonymized, Male, 70+

No recurrence of lung cancer or stroke at 10 months post-surgery.

PubMed CentralRead more →

Lung Adenocarcinoma Recurring Years After Surgery in a Woman With a Separate Rectal Neuroendocrine Tumor

Patient Info: Anonymized, female, 60s | Stage I

She died from progression of lung cancer about 12 years after the lung-cancer diagnosis and 13 years after the earlier rectal neuroendocrine-tumor procedure.

PubMed CentralRead more →

Recurrent small cell lung cancer with malignant right atrial/tricuspid valve mass removed by aspiration

Patient Info: Anonymized, Female, 50s

The immediate procedural outcome was successful removal and biopsy of the malignant right atrial/tricuspid-valve mass in the setting of recurrent small cell lung cancer.

PubMed CentralRead more →

Lung Squamous Cell Carcinoma Found During Surgery for a Rare Lung Infection

Patient Info: Anonymized, male, 60s

Nine months after surgery, follow-up showed no recurrence of the lung cancer, the Mycobacterium malmoense infection, or new radiographic lung abnormalities.

PubMed CentralRead more →

Stage IIIA EGFR lung adenocarcinoma: no recurrence after early osimertinib stop

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: EGFR exon 19 deletion mutation; elevated KL-6 and SP-D during interstitial lung disease episode

During 9 months of follow-up after osimertinib was stopped, she had no recurrence of interstitial lung disease, pulmonary embolism, or non-small cell lung cancer.

PubMed CentralRead more →